GynEC®-DX, the first molecular test to detect endometrial cancer developed entirely in Spain, is already present in the Swedish, Norwegian and Danish markets . The 39th edition of the NFOG (Nordic Congress of Obstetrics and Gynecology), held these days in Stockholm, has served as a framework for the launch of GynEC®-DX in the Scandinavian market.
